Cormark Has Pessimistic Outlook of Curaleaf FY2024 Earnings

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Investment analysts at Cormark reduced their FY2024 EPS estimates for Curaleaf in a research report issued to clients and investors on Thursday, November 7th. Cormark analyst J. Pytlak now forecasts that the company will earn ($0.27) per share for the year, down from their previous forecast of ($0.25). Cormark currently has a “Hold” rating on the stock. The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Cormark also issued estimates for Curaleaf’s FY2025 earnings at ($0.19) EPS.

Separately, Needham & Company LLC restated a “buy” rating and issued a $6.25 price objective on shares of Curaleaf in a research report on Thursday, August 8th.

Curaleaf Price Performance

CURLF stock opened at $2.04 on Monday. The stock’s 50 day moving average price is $2.93 and its 200 day moving average price is $3.75. The firm has a market cap of $1.33 billion, a P/E ratio of -7.03 and a beta of 0.86. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.50 and a current ratio of 1.09. Curaleaf has a 1 year low of $1.64 and a 1 year high of $6.40.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.